[HTML][HTML] The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer
T Kiriu, M Yamamoto, T Nagano, D Hazama, R Sekiya… - PloS one, 2018 - journals.plos.org
Background Nivolumab improves the survival of advanced non-small cell lung cancer
(NSCLC), but a significant number of patients still fail to benefit from this treatment. In this …
(NSCLC), but a significant number of patients still fail to benefit from this treatment. In this …
[HTML][HTML] Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
JV Alessi, A Price, AL Richards, B Ricciuti… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
There is a need to identify predictive biomarkers to guide treatment strategies in stage III non-
small cell lung cancer (NSCLCs). In this multi-institutional cohort of 197 patients with stage III …
small cell lung cancer (NSCLCs). In this multi-institutional cohort of 197 patients with stage III …
The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer
S Matsuura, S Serizawa, R Yamashita… - Annals of …, 2023 - Taylor & Francis
Background Adjuvant durvalumab after chemoradiation has become the standard of care for
patients with stage III NSCLC, according to the PACIFIC trial. Whether biomarkers before …
patients with stage III NSCLC, according to the PACIFIC trial. Whether biomarkers before …
[HTML][HTML] Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo-or targeted therapy
R Berardi, S Rinaldi, M Santoni, T Newsom-Davis… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Background We aimed to assess the prognostic role of neutrophilia, lymphocytopenia and
the neutrophil-to-lymphocyte ratio (NLR), and to design models to define the prognosis of …
the neutrophil-to-lymphocyte ratio (NLR), and to design models to define the prognosis of …
[HTML][HTML] Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
A Nishimura, A Ono, K Wakuda, T Kawabata… - Investigational new …, 2022 - Springer
Summary Background. Prognostic data on Japanese patients receiving durvalumab after
chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC) are …
chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC) are …
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase …
R Hui, M Özgüroğlu, A Villegas, D Daniel… - The Lancet …, 2019 - thelancet.com
Background In the ongoing, phase 3 PACIFIC trial, durvalumab improved the primary
endpoints of progression-free survival and overall survival compared with that for placebo …
endpoints of progression-free survival and overall survival compared with that for placebo …
[HTML][HTML] Pretreatment neutrophil-to-lymphocyte ratio predicts treatment efficacy and prognosis of cytotoxic anticancer drugs, molecular targeted drugs, and immune …
M Ishihara, R Ochiai, T Haruyama… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Neutrophil-to-lymphocyte ratio (NLR) has recently attracted attention as a
prognostic predictor in patients with non-small cell lung cancer (NSCLC) who receive …
prognostic predictor in patients with non-small cell lung cancer (NSCLC) who receive …
A blood-based assay for assessment of tumor mutational burden in first-line metastatic NSCLC treatment: results from the MYSTIC study
Purpose: Tumor mutational burden (TMB) has been shown to be predictive of survival
benefit in patients with non–small cell lung cancer (NSCLC) treated with immune checkpoint …
benefit in patients with non–small cell lung cancer (NSCLC) treated with immune checkpoint …
[HTML][HTML] Baseline tumour measurements predict survival in advanced non-small cell lung cancer
DE Gerber, SE Dahlberg, AB Sandler, DH Ahn… - British journal of …, 2013 - nature.com
Background: The association between tumour measurements and survival has been studied
extensively in early-stage and locally advanced non-small cell lung cancer (NSCLC). We …
extensively in early-stage and locally advanced non-small cell lung cancer (NSCLC). We …